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Abstract
Introduction: Glucagonoma syndrome is a rare paraneoplastic phenomenon, with an estimated incidence of one
in 20 million, characterized by necrolytic migratory erythema, hyperglucagonemia, diabetes mellitus, anemia,
weight loss, glossitis, cheilitis, steatorrhea, diarrhea, venous thrombosis and neuropsychiatric disturbances in the
setting of a glucagon-producing alpha-cell tumor of the pancreas. Necrolytic migratory erythema is the presenting
manifestation in the majority of cases, so its early suspicion and correct diagnosis is a key factor in the
management of the patient.
Case presentation: We present the case of a 70-year-old Caucasian woman with glucagonoma syndrome due to
an alpha-cell tumor located in the tail of the pancreas, successfully treated with surgical resection.
Conclusion: Clinicians should be aware of the unusual initial manifestations of glucagonoma. Early diagnosis
allows complete surgical resection of the neoplasm and provides the only chance of a cure.
Introduction
A glucagonoma is a slow-growing alpha-cell tumor of
the pancreatic islets of Langerhans. It may appear as a
benign and localized alpha-cell adenoma but at least
50% of cases will have metastatic disease when diag-
nosed [1]. Glucagonomas can be associated with other
tumors in Multiple Endocrine Neoplasia syndrome 1
(MEN 1), but this association is rare and comprises no
more than 3% of glucagonomas. Even though glucago-
nomas related to MEN 1 syndrome probably carry a
better prognosis due to early recognition through peri-
odic screening visits, 80% are malignant and frequently
spread to the liver [2]. Glucagonoma syndrome is a rare
paraneoplastic phenomenon, with an estimated inci-
dence of one in 20 million, characterized by necrolytic
migratory erythema (NME), hyperglucagonemia, dia-
betes mellitus, anemia, weight loss, glossitis, cheilitis,
steatorrhea, diarrhea, venous thrombosis and neuropsy-
chiatric disturbances in the setting of a glucagon-produ-
cing alpha-cell tumor of the pancreas [3]. The most
common features of this syndrome are weight loss,
NME and diabetes mellitus [4]. Of these, NME presents
as the hallmark clinical sign of glucagonoma syndrome
[3]. Its early recognition allows a prompt diagnosis of
the tumor and leads to a better prognosis. Surgery is the
optimal treatment for a glucagonoma. We present a
patient with glucagonoma syndrome due to a well cir-
cumscribed alpha-cell tumor of the pancreas, in which
surgical removal of the tumor by distal pancreatectomy
with splenectomy led to resolution of the cutaneous and
systemic features.
Case presentation
A 70-year-old Caucasian woman was referred to our
Department of Dermatology with a persistent subacute
eczema affecting her lower extremities and groin area
that had been present for 12 months. She was treated
with topical and oral steroids with no improvement. Her
medical history revealed a long-standing type 2 diabetes
mellitus and recurrent episodes of deep-vein thrombosis
in her right leg despite anticoagulant therapy. The skin
eruption initially appeared in her lower extremities but
there was a rapid progression with involvement of her
trunk, upper extremities and perioral area. These skin
lesions were associated with weight loss (15 kg in one
year), anorexia, weakness, glossitis and angular stomati-
tis. A physical examination revealed itching cutaneous
eruptions of erythematous polycyclic migratory lesions
with scaling advancing borders and central resolution.
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The entire course of the local skin lesion healed within
two weeks while new cutaneous eruptions occurred in
other locations. Chronic lesions often evolved into liche-
nification. Laboratory data showed a low hemoglobin
level (10.5 g/dL), hyperglycemia (176 mg/dL), hypoalbu-
minemia (22 g/L) and hypoproteinemia (49 g/L). Her
white cell count (6100/μL) and platelet level (26.2 ×
104/μL) were also within normal limits, and an abnorm-
ality of cell form was not found in her peripheral blood.
Her levels of serum iron, vitamin B12 and erythropoie-
tin, and the number of reticulocytes were found to be
normal. Electrophoresis of her serum protein was per-
formed because of the possibility of multiple myeloma;
however, no abnormal protein was found. Although the
possibility of gastrointestinal (GI) bleeding was consid-
ered, no abnormality was detected on an upper GI
endoscopy, barium enema, or barium examination of
her small bowel. A skin biopsy performed on a peritibial
lesion showed a spongiotic epidermis with vacuolization
of the granular layer and presence of necrotic keratino-
cytes in the horny layer. A mild infiltrate of lymphocytes
was present in the papillary dermis (Figure 1). Histologi-
cal findings were compatible with the diagnosis of NME.
Ultrasonography was performed as a screening examina-
tion, and revealed a hypoechoic tumor in her distal pan-
creas. An abdominal computed tomography (CT) scan
showed a hypervascularized tumor measuring 5 to 7 cm
in the tail of her pancreas without evidence of meta-
static disease (Figure 2). Carcinoembryonic antigen and
carbohydrate antigen 19-9 levels were normal. The exo-
crine function of her pancreas was normal. However,
her level of serum glucagon was elevated to 2340 pg/mL
(normal range, 55-177 pg/mL), while her levels of other
hormones, such as somatostatin or gastrin, were within
normal limits, and insulin was low. Glucagonoma of the
pancreas was diagnosed and distal pancreatectomy with
splenectomy was performed. This resection involved
dissection of her regional lymph nodes (D1). Histo-
pathological examination revealed a 6 cm alpha-cell
pancreatic tumor with vascular and perineural tumor
invasion. Dissection of the regional lymph nodes showed
that a total of 16 lymph nodes were isolated, of which
three were affected. Inmunohistochemical staining was
positive for glucagon, chromogranin and synaptophysin,
but negative for other hormones, such as insulin, gastrin
and somatostatin. On the basis of these findings, a diag-
nosis of malignant glucagonoma of the pancreas was
made. Five days after surgery, the skin lesions disap-
peared and postoperative plasma glucagon levels
decreased to 197 pg/dL. Our patient has been without
recurrence for one and a half years since the surgery
and remains asymptomatic.
Discussion
Stacpoole [5] reported that all of the following criteria
should be satisfied to diagnose a glucagonoma: demon-
stration of a tumor mass by direct visualization or radio-
graphic techniques; proof that the tumor shows a
preponderance of glucagon-containing cells on appropri-
ate staining and/or proof of increased tissue levels of
immunoreactive glucagon; elevation of basal circulating
immunoreactive glucagon; and at least one of the fol-
lowing coincidental findings; (a) skin rash, (b) glucose
intolerance, or (c) hypoaminoacidemia. The patient
reported here fulfilled these criteria.
The high level of glucagon secreted by the tumor may
promote glycogenolysis, gluconeogenesis, ketogenesis
and lipodieresis by activating phosphorylase in the liver,
stimulating the secretion of insulin, and inhibiting the
external secretion of the pancreas, thus resulting in the
increased level of blood glucose. In persistent hyperglu-
cagonemia, diabetes mellitus develops at the expense of
tissue glycogen stores, muscle and fat mass. Impaired
fasting glycemia or diabetes mellitus is found in 80% of
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Figure 1 Necrolytic migratory erythema. (A) Skin lesions affecting pretibial area. (B) Skin biopsy in necrolytic migratory erythema showing a
zone of necrolysis and vacuolated keratinocytes.
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patients with glucagonoma syndrome [6]. Hyperglucago-
nemia in healthy patients and in glucagonoma syndrome
reduces plasma amino acid concentrations and enhances
essential amino acid catabolism.
NME is the presenting manifestation in 70% of
patients with glucagonoma syndrome [3]. The lesions
consist of erythematous scaling and crusting patches
most frequently observed in the groin, intergluteal and
genital areas. Central healing may occur giving an annu-
lar appearance. The most specific feature on skin histo-
logical examination is necrolysis of the upper epidermis
with vacuolated keratinocytes, leading to focal or conflu-
ent necrosis, but this histopathologic feature may be
seen in other deficiency states like pellagra, necrolytic
acral erythema or zinc deficiency [4]. Normalization of
glucagon concentrations by surgery results in a rapid
disappearance of the skin rash. However, abnormal glu-
cagon levels alone cannot explain all of the skin find-
ings. Hypoaminoacidemia, nutritional lack of zinc and
fatty acids or hepatocellular dysfunctions are all consid-
ered to be possible triggering factors of NME. Hyperglu-
cagonemia provokes multiple nutrient and vitamin B
deficiencies, which in turn are the probable cause of this
typical skin disorder [7]. Other systemic pathologies,
such as chronic liver disease, inflammatory bowel dis-
ease, malabsorptive state, pancreatitis, various malignant
neoplasms and heroin abuse have been associated with
NME without glucagonoma. The early recognition of
NME is therefore important because it will prevent the
catabolic clinical features and reduce the risk of metas-
tasis with obvious quality of life improvements. Even
though NME has traditionally been considered an early
manifestation of disease, it is more likely a late manifes-
tation of years of tumor growth. The relatively low
occurrence rate of NME in patients with MEN-asso-
ciated glucagonoma diagnosed early in the clinical
course by screening efforts supports this contention
[3,8].
As seen in our patient, glucagonoma syndrome can be
associated with a high incidence of thromboembolism.
A thromboembolic phenomenon, such as deep-vein
thrombosis or pulmonary embolism, may be present in
10-30% of patients, often resulting in death. In fact,
thromboembolic events may account for over 50% of all
deaths directly attributed to the glucagonoma syndrome.
The mechanism for this coagulopathy is poorly under-
stood and seems to be related to an increased factor ×
production by the pancreatic alpha-cells [9].
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Figure 2 Radiological and histological findings. (A) Axial and (B) coronal CT scan revealing a 5-7 cm nodular mass in the tail of her pancreas
(*)(C) Histological examination of the mass showing an alpha-cell pancreatic tumor (hematoxylin and eosin ×20). (D) Inmunostaining revealed
numerous glucagon-positive cells (×20).
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Although the optimal treatment for glucagonoma is
surgery, 50% of the tumors have metastasized by the
time of diagnosis [1]. Transabdominal ultrasound has
been used to demonstrate tumor localization but has
limited utility because of its inferior sensitivity. Endo-
scopic ultrasound visualization of the tumor is report-
edly highly sensitive but has not gained widespread
acceptance. A contrast-enhanced CT scan is very useful
in attempting to demonstrate the presence of a pancrea-
tic tumor and it is usually the initial radiographic test
because of its non-invasiveness. However, selective visc-
eral angiography is considered the gold standard in diag-
nosis and localization of glucagonomas. Its superior
sensitivity is related to the hypervascularity of these neo-
plasms. Although it is an invasive test, it has the advan-
tage of being able to demonstrate hepatic metastasis
even in cases with normal liver scans. The role of mag-
netic resonance imaging (MRI) in the diagnosis of gluca-
gonoma has not been clearly defined. The utility of
pancreatic venous sampling for glucagon levels to diag-
nose smaller tumors has also been reported [5]. The
diagnosis is made by the finding of a pancreatic alpha-
cell tumor. Although the average size of a glucagonoma
may be large, diagnostic confirmation and localization
by needle biopsy is not usually performed due to the
ease and precision of alternative methods. These other
methods to localize the tumor in suspected cases
include ultrasound, CT and selective visceral angiogra-
phy. Tumors and metastases can be visualized by CT.
Neuroendocrine tumors, in contrast to pancreatic exo-
crine adenocarcinoma, are hypervascular lesions, and
this characteristic is often useful when reviewing ima-
ging studies. Somatostatin receptor scintigraphy is fre-
quently used as a complementary method to
conventional imaging such as CT and MRI as it is useful
for consistent supervision of somatostatin receptor
expression and dissemination of the tumor metastases
[4,10]. The liver is the most frequent site of metastasis,
followed by the peripancreatic lymph nodes, bone adre-
nal gland, kidney and lung.
Pancreatic endocrine tumors represent a heteroge-
neous group with varying tumor biology and prognosis.
These neoplasms are classified as functional if they are
associated with a hormone-related clinical syndrome
caused by hormone release from the tumor, or non-func-
tional if the tumor is not associated with a hormone-
related clinical syndrome [11]. The differential diagnosis
is based on histopathology demonstrating neuroendo-
crine features such as positive staining for chromogranin
A and specific hormones such as gastrin, proinsulin and
glucagon. The differential diagnosis of glucagonoma
includes other primary pancreatic neoplasms, intrapan-
creatic malignant mesothelioma, and solid pseudopapil-
lary neoplasms [12]. A close relationship between
glucagon expression in pancreatic endocrine tumors and
cystic formation is also reported in the literature, but cys-
tic glucagonomas are not associated with a glucagonoma
syndrome in the majority of cases as they are non-func-
tioning glucagon-producing neuroendocrine tumors [13].
Treatment of glucagonoma syndrome should be direc-
ted at the underlying etiology. Removal of the primary
tumor with a distal pancreatectomy brought evident
relief of all clinical symptoms for 1 to 2 year periods.
Pancreatic fistula and delayed gastric emptying are the
most prevalent complications of distal pancreatectomy
but they can be managed by conservative measures in
the majority of cases. The tumor is resistant to che-
motherapy and metastatic disease is often not amenable
to surgical resection. The prognosis of this disease varies
greatly according to the stage at which the disease is
diagnosed. Estimations of mean survival after diagnosis
have ranged from three to seven years or more [14].
Long-acting somatostatin analogues, which are potent
inhibitors of glucagon release, have been proven effec-
tive in suppressing glucagon secretion from glucagono-
mas and controlling the metastatic growth. Since the
tumor is slow growing, prolonged survival is possible
and, in metastatic disease, most causes of death appear
to be unrelated to the tumor. Control of liver metastases
by metastasectomy, cryoablation, radiofrequency abla-
tion or chemoembolization has been reported [4,6].
Recent studies suggest that conventional contraindica-
tions to surgical resection, such as superior mesenteric
vein invasion and nodal or distant metastases, should be
redefined in patients with advanced neuroendocrine
tumors. These patients will benefit from extensive surgi-
cal debulking in combination with adjuvant medical
treatments, such as somatostatin analogues. This combi-
nation may result in enhanced survival rates compared
with either procedure alone [10].
Conclusion
Clinicians should be aware of the unusual initial mani-
festations of glucagonoma. Early diagnosis allows com-
plete surgical resection of the neoplasm and provides
the only chance of a cure.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
Authors’ contributions
AML, JGT, PAM, JAP, JFF, CGB, LBS and JGG were involved in the direct care
of this patient. In addition, PGC was responsible for drafting the manuscript
and JAP, JGT and PAM helped to draft the manuscript. All authors have read
and approved the final manuscript.
Castro et al. Journal of Medical Case Reports 2011, 5:402
http://www.jmedicalcasereports.com/content/5/1/402
Page 4 of 5
Competing interests
The authors declare that they have no competing interests.
Received: 24 February 2011 Accepted: 22 August 2011
Published: 22 August 2011
References
1. Hellman P, Andersson M, Rastad J, Juhlin C, Karacagil S, Eriksson B,
Skogseid B, Akerström G: Surgical strategy for large or malignant
endocrine pancreatic tumors. World J Surg 2000, 24:1353-1360.
2. Okauchi Y, Nammo T, Iwahashi H, Kizu T, Hayashi I, Okita K, Yamagata K,
Uno S, Katsube F, Matsuhisa M, Kato K, Aozasa K, Kim T, Osuga K,
Nakamori S, Tamaki Y, Funahashi T, Miyagawa J, Shimomura I:
Glucagonoma diagnosed by arterial stimulation and venous sampling
(ASVS). Inter Med 2009, 48:1025-1030.
3. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV: The
glucagonoma syndrome. Clinical and pathologic features in 21 patients.
Medicine 1996, 75:53-63.
4. Chastain MA: The glucagonoma syndrome: a review of its features and
discussion of new perspectives. Am J Med Sci 2001, 321:306-320.
5. Stacpoole PW: The glucagonoma syndrome: clinical features, diagnosis,
and treatment. Endocr Rev 1981, 2:347-361.
6. O’Grady HL, Conlon KC: Pancreatic neuroendocrine tumours. Eur J Surg
Oncol 2008, 34:324-332.
7. van Beek AP, de Haas ER, van Vloten WA, Lips CJ, Roijers JF, Canninga-van
Dijk MR: The glucagonoma syndrome and necrolytic migratory
erythema: a clinical review. Eur J Endocrinol 2004, 151:531-537.
8. Lobo I, Carvalho A, Amaral C, Machado S, Carvalho R: Glucagonoma
syndrome and necrolytic migratory erythema. Int J Dermatol 2010,
49:24-29.
9. Teixeira RC, Nico MM, Ghideti AC: Necrolytic migratory erythema
associated with glucagonoma: a report of 2 cases. Clinics (Sao Paulo)
2008, 63:267-270.
10. Norton JA, Kivlen M, Li M, Schneider D, Chuter T, Jensen RT: Morbidity and
mortality of aggressive resection in patients with advanced
neuroendocrine tumors. Arch Surg 2003, 138:859-866.
11. Öberg K: Pancreatic endocrine tumors. Semin Oncol 2010, 37:594-618.
12. Papavramidis T, Papavramidis S: Solid pseudopapillary tumors of the
pancreas: review of 718 patients reported in English literature. J Am Coll
Surg 2005, 100:965-972.
13. Konukiewitz B, Enosawa T, Klöppel G: Glucagon expression in cystic
pancreatic neuroendocrine neoplasms: an immunohistochemical
analysis. Virchows Arch 2011, 458:47-53.
14. Schwartz RA: Glucagonoma and pseudoglucagonoma syndromes. Int J
Dermatol 1997, 36:81-89.
doi:10.1186/1752-1947-5-402
Cite this article as: Castro et al.: Glucagonoma syndrome: a case report.
Journal of Medical Case Reports 2011 5:402.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Castro et al. Journal of Medical Case Reports 2011, 5:402
http://www.jmedicalcasereports.com/content/5/1/402
Page 5 of 5
